Díaz Rosa, Soundar Esther, Hartman S Kate, Dreyer ZoAnn, Teruya Jun, Hui Shiu-Ki Rocky
1Department of Pediatrics, Texas Children's Hospital , Houston, TX , USA.
Pediatr Hematol Oncol. 2014 Aug;31(5):425-34. doi: 10.3109/08880018.2013.868562. Epub 2014 Jan 2.
Transfusions of granulocytes can be used as an adjunct therapy to antimicrobials in patients with infection and neutropenia or granulocyte dysfunction. However, there is a lack of strong clinical evidence to support the use of this treatment strategy, particularly in children. We retrospectively reviewed the medical records of children who received granulocytes at our institution from April 2009 to October 2012, with emphasis on primary indication for the transfusion and clinical outcome in terms of infection. The patients had granulocyte dysfunction or severe neutropenia, defined as absolute neutrophil count (ANC) < 500 cells/mm(3) due to chemotherapy or hematopoietic stem cell transplant (HSCT), and reasonable hope for bone marrow recovery or engraftment. Eighteen children received granulocytes during 20 distinct episodes: 62% (n = 13) for acute infection, 29% (n = 5) for unresolved chronic infection during the time of HSCT, and 9% (n = 2) for other clinical conditions such as typhilitis and appendectomy. Overall, 92% (n = 12) of the episodes of acute infection had complete or partial resolution, as determined by review of vital signs, physical exam findings and discontinuation of antimicrobials. A substantial number (46%) of children who received granulocytes for acute infection developed respiratory adverse events, but all of these recovered. We conclude that granulocyte transfusions continue to be primarily used in neutropenic patients with acute infections, and that its use in this group of patients is reasonable. However, a prospective randomized clinical trial is needed to evaluate safety and whether the use of granulocytes is superior to antimicrobial-only therapy.
对于感染且伴有中性粒细胞减少或粒细胞功能障碍的患者,粒细胞输注可作为抗菌药物的辅助治疗。然而,缺乏有力的临床证据支持这种治疗策略的使用,尤其是在儿童中。我们回顾性分析了2009年4月至2012年10月在我院接受粒细胞输注的儿童的病历,重点关注输血的主要指征以及感染方面的临床结局。这些患者存在粒细胞功能障碍或严重中性粒细胞减少,定义为因化疗或造血干细胞移植(HSCT)导致的绝对中性粒细胞计数(ANC)<500个细胞/mm³,且骨髓恢复或植入有合理希望。18名儿童在20次不同的情况下接受了粒细胞输注:62%(n = 13)用于急性感染,29%(n = 5)用于HSCT期间未解决的慢性感染,9%(n = 2)用于其他临床情况,如盲肠炎和阑尾切除术。总体而言,通过对生命体征、体格检查结果和抗菌药物停用情况的评估,92%(n = 12)的急性感染情况得到了完全或部分缓解。大量(46%)因急性感染接受粒细胞输注的儿童出现了呼吸道不良事件,但所有这些都康复了。我们得出结论,粒细胞输注仍主要用于患有急性感染的中性粒细胞减少患者,并且在这组患者中使用是合理的。然而,需要进行一项前瞻性随机临床试验来评估安全性以及粒细胞的使用是否优于仅使用抗菌药物的治疗。